Twice-Weekly Subcutaneous Testosterone at 70mg is a Reasonable and Increasingly Common Schedule
Yes, injecting 70mg of testosterone subcutaneously twice weekly (Sunday and Wednesday mornings) is a normal and clinically appropriate schedule that falls within evidence-based dosing parameters.
Why This Schedule Works
The twice-weekly regimen you describe (140mg total per week, split into two 70mg doses) aligns well with current clinical practice and emerging evidence. While traditional guidelines primarily reference intramuscular (IM) administration, the principles and total weekly dosing translate effectively to subcutaneous (SC) administration 1.
Dosing Context
Total weekly dose: Your 140mg/week falls within the recommended range. Guidelines suggest 50-150mg of testosterone enanthate or cypionate IM at 7-14 day intervals 1, and the 2006 Endocrine Society guideline specifically mentions 75-100mg IM weekly 2.
Frequency rationale: More frequent injections with smaller doses maintain more stable testosterone levels and reduce peak-trough fluctuations 3, 4. This minimizes early peak-related symptoms (acne, mood swings, fluid retention) and late-cycle hypogonadal symptom recurrence 3.
Subcutaneous Route Validation
The subcutaneous route is well-supported by recent evidence 4, 5, 6. Studies demonstrate that SC testosterone administration:
- Produces comparable pharmacokinetics to IM injections 4, 6
- Achieves physiologic testosterone levels when dosed appropriately 5, 6
- Is easier to self-administer with less discomfort 4, 5
- Shows excellent safety profiles with minimal injection site reactions 5
A 52-week study of SC testosterone enanthate found that 92.7% of patients achieved target testosterone levels (300-1,100 ng/dl) with weekly dosing, with over 95% reporting no injection-related pain 5.
Important Monitoring Requirements
Regardless of your dosing schedule, you must follow established monitoring protocols 7:
Initial Monitoring (3-6 months after starting):
- Testosterone level: Should be measured midway between injections (approximately 3-4 days after your last dose). Target is mid-normal range (450-600 ng/dl) 7, 8.
- Hematocrit: Critical safety parameter. Stop therapy if >54% 7.
- PSA and digital rectal exam (if age 40+ with baseline PSA >0.6 ng/ml) 7.
Ongoing Monitoring (annually):
- Symptom response assessment
- Hematocrit checks
- PSA monitoring per age-appropriate guidelines
- Cardiovascular symptom surveillance 8
Common Pitfalls to Avoid
Don't measure testosterone at random times: The timing of blood draws relative to your injection matters significantly. For twice-weekly dosing, measure approximately 3-4 days after injection for the most interpretable results 3.
Don't ignore hematocrit elevation: This is the most common reason for dose reduction or therapy discontinuation. Baseline hematocrit >50% requires evaluation before starting therapy 7.
Don't assume more frequent = better: While twice-weekly dosing provides stable levels for many patients, some do well with weekly dosing. The goal is stable symptoms with acceptable monitoring results, not maximizing injection frequency 3.
Don't use testosterone if planning fertility: Exogenous testosterone suppresses spermatogenesis and can cause azoospermia [8, @23@].
When to Adjust
Consider dose or frequency adjustment if you experience:
- Symptom cycling (feeling great early in the week, declining by next injection)
- Acne, oily skin, or mood changes shortly after injections
- Persistent hypogonadal symptoms despite therapy
- Hematocrit trending upward toward 54%
- Testosterone levels consistently >700 ng/dl or <400 ng/dl 7
Your specific regimen of 70mg twice weekly SC is well within the therapeutic range and represents a modern, evidence-informed approach to testosterone replacement that prioritizes stable hormone levels and patient convenience.